

Pharmacologic inhibition of phospholipid transfer protein activity reduces

ApoB secretion from hepatocytes

Yi Luo, Lorraine Shelly, Thomas Sand, George Chang, Mary MacDougall,

Marie-Claire Peakman, Xian-Cheng Jiang

Department of Cardiovascular and Metabolic Diseases (Y.L, L.S, T.S, G.C, M.M, M.P),

Pfizer Global Research Division, Pfizer Inc, Eastern Point Road, Groton, CT06340.

Department of Anatomy and Cell Biology (X.J), SUNY Downstate Medical Center,

Brooklyn, NY 11203

Running title: Regulation of apoB secretion by PLTP inhibitor

Corresponding Author: Yi Luo

Address: Eastern Point Road,

MS 8220-3337, Pfizer Inc,

Groton CT 06340


Tel: 860-715-3198

Fax: 960-715-0310


E-mail: yi.luo@pfizer.com.

Supplemental Figure 1: Effect of compound A and CETP inhibitor torcetrapib on human CETP activity. The cholesterol ester transfer activity of human plasma CETP activity was measured in the presence of 0-30 μ M of testing compounds as previously in article by Clark RW, et al, *Arterioscler Thromb Vasc Biol.* 2004, 24(3):490-7.


Supplemental Figure 2: Transferrin and apoB levels in medium from Huh7 (a) and HepG2 cells (b) treated with compound A and CP-346086.



Supplemental Figure 1



Supplemental Figure 2a



Supplemental Figure 2b